During Tuesday’s Morning trade, Shares of Priceline Group Inc (NASDAQ:PCLN), gained 0.66% to $1,319.82.
The Priceline Group, stated its 3rd quarter 2015 financial results. Third quarter gross travel bookings for The Priceline Group (the “Group”), which refers to the total dollar value, generally inclusive of all taxes and fees, of all travel services purchased by its customers, were $14.8 billion, an improvement of 7% over a year ago (about 22% on a constant currency basis).
The Group’s gross profit for the 3rd quarter was $2.9 billion, a 12% improvement from the preceding year (about 29% on a constant currency basis). International operations contributed gross profit in the 3rd quarter of $2.6 billion, an 11% improvement as compared to a year ago (about 29% on a constant currency basis). The Group had GAAP net income applicable to common shareholders for the 3rd quarter of $1.2 billion, or $23.41 per diluted share, which compares to $1.1 billion or $20.03 per diluted share, in the same period a year ago.
Non-GAAP net income in the 3rd quarter was $1.3 billion, a 10% improvement as compared to the preceding year. Non-GAAP net income was $25.35 per diluted share, contrast to $22.16 per diluted share a year ago. FactSet consensus for the 3rd quarter 2015 was $24.21 per diluted share. Adjusted EBITDA for the 3rd quarter 2015 was $1.6 billion, an improvement of 12% as compared to a year ago. The section below entitled “Non-GAAP Financial Measures” provides definitions and information about the use of non-GAAP financial measures in this press release, and the attached financial and statistical supplement reconciles non-GAAP financial information with the Group’s financial results under GAAP.
“The Priceline Group delivered strong growth and operating results during its high travel season,” said Darren Huston, President and CEO of The Priceline Group. “Globally, our accommodation business booked a record 116 million room nights in the 3rd quarter, up 22% over the same period last year. Gross profit grew 29% on a constant currency basis. Booking.com showed continued positive momentum with over 820,000 properties on its platform, up 38% over last year. This represents over 21 million potentially bookable rooms, the largest, and most diverse, selection of directly bookable accommodations in the world.”
The Priceline Group Inc. provides online travel and travel related reservation and search services. The company operates Booking.com, which provides online accommodation reservation services; and priceline.com that offers hotel, rental car, and airline ticket reservations services, in addition to vacation packages and cruises through its Name Your Own Price and Express Deals travel services.
Shares of 3D Systems Corporation (NYSE:DDD), declined -3.37% to $9.75, during its current trading session.
3D Systems, declared that it will be taking part in form next 2015, a new trade fair for moldmaking, product design and 3D printing that will be debuting this year in Frankfurt, Germany, November 17-20.
3DS will showcase the full power of its digital thread solutions for software and 3D printing, demonstrating the seamless design-to-manufacturing workflow it enables for professionals and businesses across industries. Among the products and capabilities on display will be the Pro Jet(R) 4500, Pro Jet(R) 5500X and the Cube Pro(R) desktop 3D printer. Visitors to the show will be able to witness firsthand the accuracy and detail of the Pro X(TM) 100 Direct Metal Printer as it creates highly complex metal parts live on the show floor.
3DS’ integrated solutions enhance, complement or replace traditional manufacturing methods through 3D scanning, design, production and inspection. These solutions lead to improved part performance and raised productivity within teams and organizations.
Visitors to formnext can find 3DS in Hall 3.1, booth E78, where they will be able to experience 3DS’ latest design-to-manufacturing solutions, counting:
- Direct metal 3D printing using the Pro X(TM) 100. The Pro X series of Direct Metal Printers creates chemically pure, fully dense metal parts with thin walls, excellent surface finish and detail resolution, perfect for custom dental prostheses, tire molds, watch manufacturing, aerospace parts and more.
- High-performance, multi-material composite 3D printing using the Pro Jet(R) 5500X. This versatile 3D printer simultaneously prints and blends flexible and rigid materials layer by layer at the pixel level, so users can quickly create multi-material assemblies, over molded parts, rubber-like components and more.
- Desktop prototyping and end-use parts on the Cube Pro(R) 3D printer. Offering the largest-in-class build platform, high resolutions and fast print times, with advanced material options in Nylon and Infinity(TM) Rinse-Away support, the Cube Pro is the perfect desktop printer for engineers, hobbyists, architects, and more.
- Engineering software and hardware tools for the digital thread for manufacturing, counting Geomagic Capture and Geomagic Design X 2016 for seamless scan-to-CAD modeling, Geomagic Freeform tools for precise organic design, GibbsCAM production machining software and CimatronE mold and tool design. Each of these highly capable products integrates with both traditional manufacturing and 3D printing technologies for faster and more accurate design and parts production.
- Quickparts(R) on-demand parts service, providing advanced prototyping and manufacturing solutions through cloud-based fulfillment. With instant online quoting and a global team of 3D printing experts committed to customer success, Quickparts connects designers, engineers and manufacturers with an expansive array of 3D printing technologies, materials and finishing options—from anywhere in the world, at any time.
3D Systems Corporation, through its auxiliaries, operates as a provider of 3D printing centric design-to-manufacturing solutions in the Americas, Germany, and the Asia-Pacific, in addition to other European, the Middle East, and African countries. The company’s 3D printers transform data input from the format generated by 3D design software, CAD software, or 3D scanning and sculpting devices to printed parts using integrated, engineered plastic, metal, nylon, rubber, wax, and composite print materials.
Finally, Shares of Incyte Corporation (NASDAQ:INCY), gained 0.43%, and is now trading at $106.17.
Eli Lilly and Company and Incyte Corporation, declared detailed data from pivotal phase 3 study RA-BEAM, the fourth successful phase 3 study of baricitinib, at the American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting in San Francisco . The findings demonstrated statistical superiority for investigational therapy baricitinib over adalimumab (Humira) after 12 weeks based on several critical measures of rheumatoid arthritis (RA) disease activity, counting ACR20, ACR50 and ACR70 response rates — composite scores that represent at least a 20 percent, 50 percent and 70 percent improvement in multiple components of RA disease activity.
Improvements in mean number of swollen and tender joints and a reduction in pain were seen as early as one week for baricitinib as compared to placebo. At 52 weeks, baricitinib significantly improved all seven components of the ACR composite score contrast to adalimumab, counting reducing the number of tender and swollen joints, reducing patients’ pain and improving physical function. Patient-stated outcomes, counting degree of tiredness and the severity and duration of morning joint stiffness, assessed daily for the first 12 weeks of the study, were all significantly improved with baricitinib contrast to adalimumab.
At week 52, structural changes in the joints, as measured by changes in the modified Total Sharp Score, were significantly improved for both baricitinib and adalimumab contrast with placebo. Lilly and Incyte formerly declared that the study met its primary objective of demonstrating superiority for baricitinib as compared to placebo based on ACR20 response rate after 12 weeks of treatment.
“Rheumatoid arthritis is a lifelong condition, but it can be managed with treatment to assist control symptoms, counting joint inflammation and fatigue, to slow the progression of the disease and improve a patient’s quality of life,” said Peter Taylor , M.A., Ph.D., F.R.C.P., study author and Norman Collisson chair of Musculoskeletal Sciences in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford . “These findings suggest that the once-daily oral drug baricitinib, if approved, could provide another treatment option for those with insufficient response to current therapy.”
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.